Endoron Medical
Endoron Medical (“Endoron”), a pioneering medtech company specialising in innovative endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms, announced the successful closing of its 10 million USD Series A funding round. The round was led by Sofinnova Partners, with significant matching contributions from the European Innovation Council Fund (EIC Fund).
The capital received will accelerate the clinical validation of Endoron’s flagship product, the catheter-based EndoStapling solution Aortoseal, as it progresses through its Investigational Device Exemption (IDE) approved Early Feasibility Study (EFS).
"Sofinnova Partners are the go-to investors within medtech. They bring a wealth of operational experience working with high-growth companies like ours," said Ronit Harpaz, co-founder and CEO of Endoron. "With their continued support, I am confident we will reach key clinical and regulatory milestones as we advance our EndoStapling technology towards the clinic. The EIC’s participation further solidifies our commitment to bringing this innovative solution to the European market."
Endoron is at the forefront of developing advanced technologies for the endovascular repair of abdominal aortic aneurysms (AAA). Its technology addresses the critical challenges of sealing and securing endografts used in minimally invasive AAA repairs, particularly in complex procedures. Endoron’s innovative stapling mechanism ensures complete sealing of endografts while securely anchoring them, preventing long-term migration and endoleaks, thereby reducing the need for highly invasive, high-mortality open surgeries.
“Endoron is a clear example of Sofinnova Partners MD Start’s acceleration strategy which identifies promising innovation at the earliest stages and provides capital as well as operational expertise via our team of serial entrepreneurs. We believe that Endoron’s innovative EndoStapling has the potential to revolutionise endovascular repair of AAA, and we are excited to support them in their journey,” said Cécile Dupont, Partner at Sofinnova Partners' medtech accelerator, MD Start.
Svetoslava Georgieva, Chair of the EIC Fund Board, said: “We are very happy to participate in this funding round for Endoron. EIC Fund’s investment will help them advance their endovascular repair solution and reduce complications and reinterventions for patients.”
With the successful completion of this funding round, Endoron is well-positioned to capitalise on the growing market opportunity to drive innovation in endovascular care. The company remains committed to advancing endovascular repair solutions to improve patient outcomes.
